Short-term outcomes of laparoscopy-assisted gastrectomy with D2 lymph node dissection for gastric cancer: Experience from a single institution in central Vietnam

Abstract

Introduction: Laparoscopic-assisted gastrectomy (LAG) has become more popular and extensively developed for gastric cancer. However, LAG with D2 lymph node (LN) dissection has not been widely deployed because it is a complex technique and should be performed by experienced laparoscopic surgeons. This study aimed to confirm the feasibility and outcomes of the LAG with D2 dissection for gastric cancer.

Patients and Methods: The prospective intervention study included 72 patients with gastric cancer and underwent LAG with D2 LN dissection between April 2017 and October 2021. All patients were operated by the same surgeon who had experience with laparoscopy. LAG with conventional D2 lymphadenectomy is based on the Japanese gastric cancer treatment guidelines 2014 (ver. 4).

Results: The LAG includes 31 (43.1%) total gastrectomies and 41 (56.9%) distal gastrectomies. Conversion to open laparotomy was required in one patient (1.4%). The mean number of harvested lymph nodes was 20.4 ±

9.1 (range 4 – 47). In 75.0% of the procedures, at least 15 lymph nodes were resected. The mean number of positive lymph nodes was 4.2 ± 5.7 (range 0 – 21), and 16.2 ± 9.3 negative lymph nodes (range 0 – 47). The mean operative time was 231.8 ± 38.1 minutes (range 170 – 350). The mean time to first flatus was 3.5 ± 1.0 days (range 2 – 7). The mean postoperative hospital stay was 10.8 ± 4.0 days (range 7 – 30). The complications within 30 postoperative days occurred in 12 patients (16.7%).

Conclusions: Laparoscopy-assisted gastrectomy with D2 LN dissection was safe and feasible with favorable short-term oncological outcomes. However,this technique must be realized by experienced surgeons in specialized centers.

Keywords: Gastric cancer, Laparoscopy-assisted gastrectomy, D2 dissection, Vietnam

References

1. Sung et al., “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA. Cancer J. Clin., vol. 71, no. 3, pp. 209–249, May 2021, doi: 10.3322/caac.21660.
2. A. Naffouje and G. I. Salti, “Extensive Lymph Node Dissection Improves Survival among American Patients with Gastric Adenocarcinoma Treated Surgically: Analysis of the National Cancer Database,” J. Gastric Cancer, vol. 17, no. 4, p. 319, 2017, doi: 10.5230/ jgc.2017.17.e36.
3. A. Mirkin, C. S. Hollenbeak, and J. Wong, “Greater Lymph Node Retrieval Improves Survival in Node- Negative Resected Gastric Cancer in the United States,” J. Gastric Cancer, vol. 17, no. 4, p. 306, 2017, doi: 10.5230/jgc.2017.17.e35.
4. Kitano, Y. Iso, M. Moriyama, and K. Sugimachi, “Laparoscopy-assisted Billroth I gastrectomy.,” Surg. Laparosc. Endosc., vol. 4, no. 2, pp. 146–8, Apr. 1994, [Online]. Available: http://www.ncbi.nlm.nih.gov/ pubmed/8180768.
5. “Japanese gastric cancer treatment guidelines 2018 (5th edition),” Gastric Cancer, 24, no. 1, pp. 1–21, Jan. 2021, doi: 10.1007/s10120-020-01042-y.
6. Qiu and Z. Zhou, “[Updates and interpretation on NCCN clinical practice guidelines for gastric cancer 2017 version 5].,” Zhonghua Wei Chang Wai Ke Za Zhi, vol. 21, no. 2, pp. 160–164, Feb. 2018, [Online]. Available: http://www.ncbi.nlm.nih.gov/ pubmed/29492914.
7. Katai et al., “Short-term surgical outcomes from a phase III study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/ IB gastric cancer: Japan Clinical Oncology Group Study JCOG0912,” Gastric Cancer, vol. 20, no. 4, pp. 699–708, Jul. 2017, doi: 10.1007/s10120-016-0646-9.
8. -J. Lee et al., “Short-term Outcomes of a Multicenter Randomized Controlled Trial Comparing Laparoscopic Distal  Gastrectomy    With    D2    Lymphadenectomy to Open Distal Gastrectomy for Locally Advanced Gastric Cancer (KLASS-02-RCT),” Ann. Surg., vol. 270, no. 6, pp. 983–991, Dec. 2019, doi: 10.1097/ SLA.0000000000003217.
9. Hu et al., “Morbidity and Mortality of Laparoscopic Versus Open D2 Distal Gastrectomy for Advanced Gastric Cancer: A Randomized Controlled Trial,” J. Clin. Oncol., vol. 34, no. 12, pp. 1350–1357, Apr. 2016, doi: 10.1200/JCO.2015.63.7215.
10. C. Smyth, M. Verheij, W. Allum, D. Cunningham,
11. Cervantes, and D. Arnold, “Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up,” Ann. Oncol., vol. 27, pp. v38–v49, Sep. 2016, doi: 10.1093/annonc/mdw350.
12. Shen et al., “Prospective randomized controlled trial to compare laparoscopic distal gastrectomy (D2 lymphadenectomy plus complete mesogastrium excision, D2 + CME) with conventional D2 lymphadenectomy for locally advanced gastric adenocarcinoma: study protocol for a ra,” Trials, vol. 19, no. 1, p. 432, Dec. 2018, doi: 10.1186/s13063-018- 2790-5.
13. A. Abdelhamed et al., “Laparoscopic gastrectomy with D2 lymphadenectomy for gastric cancer: initial Egyptian experience at the National Cancer Institute,”
14. Egypt. Natl. Canc. Inst., vol. 32, no. 1, p. 10, Dec. 2020, doi: 10.1186/s43046-020-00023-7.
15. Inaki et al., “A Multi-institutional, Prospective, Phase II Feasibility Study of Laparoscopy-Assisted Distal Gastrectomy with D2 Lymph Node Dissection for Locally Advanced Gastric Cancer (JLSSG0901),” World J. Surg., vol. 39, no. 11, pp. 2734–2741, Nov. 2015, doi: 10.1007/s00268-015-3160-z.
16. K. Park et al., “Laparoscopy-assisted versus Open D2 Distal Gastrectomy for Advanced Gastric Cancer,” Ann. Surg., vol. 267, no. 4, pp. 638–645, Apr. 2018, doi: 10.1097/SLA.0000000000002168.
17. -X. Lin et al., “Laparoscopy-assisted gastrectomy with D2 lymph node dissection for advanced gastric cancer without serosa invasion: a matched cohort study from South China,” World J. Surg. Oncol., vol. 11, no. 1, p. 4, Dec. 2013, doi: 10.1186/1477-7819-11-4.
18. Shi et al., “Short-term surgical outcomes of a randomized controlled trial comparing laparoscopic versus open gastrectomy with D2 lymph node dissection for advanced gastric cancer,” Surg. Endosc., vol. 32, no. 5, pp. 2427–2433, May 2018, doi: 10.1007/s00464-017- 5942-x.
19. J. Eshuis, M. I. van Berge Henegouwen, W. A. Draaisma, and S. S. Gisbertz, “Compliance to D2 lymphadenectomy in laparoscopic gastrectomy,” Updates Surg., vol. 70, no. 2, pp. 197–205, Jun. 2018, doi: 10.1007/s13304-018-0553-1.
20. Nakagawa et al., “Staging for Remnant Gastric Cancer: The Metastatic Lymph Node Ratio vs. the UICC 7th Edition System,” Ann. Surg. Oncol., vol. 23, no. 13, pp. 4322–4331, Dec. 2016, doi: 10.1245/ s10434-016-5390-1.
21. Ye et al., “Does Lymphadenectomy with at Least

15 Perigastric Lymph Nodes Retrieval Promise an Improved Survival for Gastric Cancer: A Retrospective Cohort Study in Southern China,” J. Cancer, vol. 10, no. 6, pp. 1444–1452, 2019, doi: 10.7150/jca.28413.

20. Chen et al., “Totally Laparoscopic Distal Gastrectomy with D 2 Lymphadenectomy and Billroth II Gastrojejunostomy for Gastric Cancer: Short- and Medium-term Results of 139 Consecutive Cases from a Single Institution,” Int. J. Med. Sci., vol. 10, no. 11, pp. 1462–1470, 2013, doi: 10.7150/ijms.6632.
21. Aoyama et al., “Equivalent feasibility and safety of perioperative care by ERAS in open and laparoscopy- assisted distal gastrectomy for gastric cancer: a single- institution ancillary study using the patient cohort enrolled in the JCOG0912 phase III trial,” Gastric Cancer, vol. 22, no. 3, pp. 617–623, May 2019, doi: 10.1007/s10120-018-0873-3.
22. J. F. Brenkman et al., “Postoperative Outcomes of Minimally Invasive Gastrectomy Versus Open Gastrectomy During the Early Introduction of Minimally Invasive Gastrectomy in the Netherlands,” Ann. Surg., vol. 266, no. 5, pp. 831–838, Nov. 2017, doi: 10.1097/ SLA.0000000000002391.
23. Hayashi et al., “Number of retrieved lymph nodes is an independent prognostic factor after total gastrectomy for patients with stage III gastric cancer: propensity score matching analysis of a multi-institution dataset,” Gastric Cancer, vol. 22, no. 4, pp. 853–863, Jul. 2019, doi: 10.1007/s10120-018-0902-2.
24. Shinohara, “Laparoscopic Total Gastrectomy With D2 Lymph Node Dissection for Gastric Cancer,” Arch. Surg., vol. 144, no. 12, p. 1138, Dec. 2009, doi: 10.1001/ archsurg.2009.223.
25. Kim et al., “Decreased Morbidity of Laparoscopic Distal Gastrectomy Compared With Open Distal Gastrectomy for Stage I Gastric Cancer,” Ann. Surg., vol. 263, no. 1, pp. 28–35, Jan. 2016, doi: 10.1097/ SLA.0000000000001346.
26. Wang et al., “Short-term surgical outcomes of laparoscopy-assisted versus open D2 distal gastrectomy for locally advanced gastric cancer in North China: a multicenter randomized controlled trial,” Surg. Endosc., vol. 33, no. 1, pp. 33–45, Jan. 2019, doi: 10.1007/ s00464-018-6391-x.
27. Yue and X. Geng, “Impact of conversion during laparoscopic gastrectomy on outcomes of patients with gastric cancer.,” J. BUON., vol. 22, no. 4, pp. 926–931, 2017, [Online]. Available: http://www.ncbi.nlm.nih. gov/pubmed/29155522.
28. C. Kim  et  al.,  “Risk  Factors  Associated  with Complication Following Laparoscopy-Assisted Gastrectomy for Gastric Cancer: A Large-Scale Korean Multicenter Study,” Ann. Surg. Oncol., vol. 15, no. 10, pp. 2692–2700, Oct. 2008, doi: 10.1245/s10434-008- 0075-z.